Very-low-density lipoprotein to low-density lipoprotein conversion

VLDL-to-LDL conversion is a fundamental metabolic process in human lipid homeostasis where triglyceride-rich very-low-density lipoproteins (VLDL) are sequentially hydrolyzed into intermediate-density lipoproteins (IDL) and ultimately into cholesterol-rich low-density lipoproteins (LDL) (Source: StatPearls, Lipoprotein Metabolism). This metabolic cascade is primarily mediated by the enzymatic activity of Lipoprotein Lipase (LPL) and Hepatic Lipase (HL), which remove triglycerides from the lipoprotein core. The rate of conversion is tightly regulated by various apolipoproteins, such as ApoC-III, and proteins like ANGPTL3, which serve as major pharmacological targets for dyslipidemia (Source: Journal of Lipid Research). Dysregulation of this pathway, characterized by overproduction of VLDL or impaired remnant clearance, leads to elevated levels of atherogenic particles and is a significant risk factor for the development of atherosclerosis and coronary heart disease. Therapeutic strategies involve the use of fibrates to stimulate LPL activity or biological agents to inhibit regulators like ApoC-III and ANGPTL3, effectively lowering plasma lipid levels and mitigating cardiovascular risk (Source: Nature Reviews Cardiology).

Other names

VLDL catabolismVLDL-IDL-LDL cascadeEndogenous lipoprotein remodelingLipoprotein conversion pathway

Drugs targeting this pathway typically modulate the activity of enzymes or regulatory proteins that govern the conversion process. Fibrates activate PPAR-alpha to increase the expression of Lipoprotein Lipase (LPL), the primary enzyme responsible for VLDL triglyceride hydrolysis (Source: PubMed, 25149826). Newer therapies like Evinacumab (an ANGPTL3 inhibitor) or Volanesorsen (an ApoC-III antisense oligonucleotide) work by inhibiting endogenous proteins that naturally suppress LPL, thereby accelerating the conversion and clearance of VLDL remnants and reducing the formation of LDL (Source: NEJM, 33230452; Nature Reviews Cardiology, 2021).